Piper Sandler analyst Matt O’Brien initiated coverage of Penumbra with an Overweight rating and $275 price target. The company’s "innovative" Lightning and Thunderbolt technologies for blood clot removal from the peripheral and neurovasculature address an $8.2B market opportunity just in the U.S., the analyst tells investors in a research note. Piper sees "significant room" for increased penetration in the end markets, setting up Penumbra for strong growth going forward.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PEN: